37
Views
3
CrossRef citations to date
0
Altmetric
Review

21st Century treatment of diabetic retinopathy

, &
Pages 623-631 | Published online: 10 Jan 2014

References

  • Girach A, Manner D, Porta M. Diabetic microvascular complications: can patients at risk be identified? A review. Int. J. Clin. Pract.60(11), 1471–1483 (2006).
  • Wilkinson CP, Ferris FL, Klein RE et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology110(9), 1677–1682 (2003).
  • Jain A, Sarraf D, Fong D. Preventing diabetic retinopathy through control of systemic factors. Curr. Opin. Ophthalmol.14(6), 389–394 (2003).
  • The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med.329(14), 977–986 (1993).
  • UKPDS Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet352(9131), 837–853 (1998).
  • Funatsu H, Yamashita H. Pathogenesis of diabetic retinopathy and the renin–angiotensin system. Ophthalmic Physiol. Opt.23(6), 495–501 (2003).
  • Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM. Risk of progression of retinopathy and visual loss related to tight control of blood pressure in Type 2 diabetes mellitus. UKPDS 69. Arch. Ophthalmol.122(11), 1631–1640 (2004).
  • Sheth HG, Aslam S, Davies N. Lipid lowering drugs in diabetes: lipid lowering has ophthalmic benefits. Br. Med. J.332(7552), 1272–1273 (2006).
  • Sjolie AK. Prospects for angiotensin receptor blockers in diabetic retinopathy. Diabetes Res. Clin. Pract.76(Suppl. 1), S31–S39 (2007).
  • Lang GE. Laser treatment of diabetic retinopathy. Dev. Ophthalmol.39, 48–68 (2007).
  • Yi Q, Bamroongsuk P, McCarty DJ, Mukesh BN, Harper CA. Clinical outcomes following laser photocoagulation treatment for diabetic retinopathy at a large Australian ophthalmic hospital. Clin. Experiment. Ophthalmol.31(4), 305–309 (2003).
  • Neubauer AS, Ulbig MW. Laser treatment in diabetic retinopathy. Ophthalmologia221(2), 95–102 (2007).
  • Lewis H. Role of vitrectomy in the treatment of diabetic macular edema. Am. J. Ophthalmol.131(1), 123–125 (2001).
  • Kuppermann BD, Thomas EL, de Smet MD, Grillone LR. Vitrase® for Vitreous Hemorrhage Study Groups. Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreous injectin of highly purified ovine hyaluronidase (Vitrase®) for the management of vitreous hemorrhage. Am. J. Ophthalmol.140(4), 573–584 (2005).
  • Kuppermann BD, Thomas EL, de Smet MD, Grillone LR. Vitrase® for Vitreous Hemorrhage Study Groups. Safety results of two Phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase®) for the management of vitreous hemorrhage. Am. J. Ophthalmol140(4), 585–597 (2005).
  • Trese MT. Enzymatic-assisted vitrectomy. Eye16(4), 365–368 (2002).
  • Sakuma T, Tanaka M, Mizota A et al. Safety of in vivo pharmacologic vitreolysis with recombinant microplasmin in rabbit eyes. Invest. Ophthalmol. Vis. Sci.46(9), 3295–3299 (2005).
  • Setter SM, Campbell RK, Cahoon CJ. Biochemical pathways for microvascular complications of diabetes mellitus. Ann. Pharmacother.37(12), 1858–1866 (2003).
  • Frank RN. Diabetic retinopathy. N. Engl. J. Med.350(1), 48–58 (2004).
  • Chung SS, Chung SK. Aldose reductase in diabetic microvascular complications. Curr. Drug Targets6(4), 475–86 (2005).
  • Sun W, Oates PJ, Coutcher JB, Gerhardinger C, Lorenzi M. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes55(10), 2757–2762 (2006).
  • Lang GE. Treatment of diabetic retinopathy with protein kinase C subtype Β inhibitor. Dev. Ophthalmol.39, 157–165 (2007).
  • Idris I, Donnelly R. Protein kinase C β inhibition: a novel therapeutic strategy for diabetic microangiopathy. Diab. Vasc. Dis. Res.3(3), 172–178 (2006).
  • The PKC–DRS Study Group: The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C β Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes54(7), 2188–2197 (2005).
  • Aiello LP, Davis MD, Girach A et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology113(12), 2221–2230 (2006).
  • Pomero F, Allione A, Beltramo E et al. Effects of protein kinase C inhibition and activation on proliferation and apoptosis of bovine retinal pericytes. Diabetologia46(3), 416–419 (2003).
  • Hammes HP, Du X, Edelstein D et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat. Med.9(3), 294–299 (2003).
  • Krady JK, Basu A, Allen CM et al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes54(5), 1559–1565 (2005).
  • Chibber R, Ben-Mahmud BM, Chibber S, Kohner EM. Leukocytes in diabetic retinopathy. Curr. Diabetes Rev.3(1), 3–14 (2007).
  • Joussen AM, Poulaki V, Le ML et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J.18(12), 1450–1452 (2004).
  • Adamis AP. Is diabetic retinopathy an inflammatory disease? Br. J. Ophthalmol.86(4), 363–365 (2002).
  • Joussen AM, Poulaki V, Mitsiades N et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-suppression. FASEB J.16(3), 438–440 (2002).
  • Zheng L, Howell SJ, Hatala DA, Huang K, Kern TS. Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes56(2), 337–345 (2007).
  • Bergerhoff K, Clar C, Richter B. Aspirin in diabetic retinopathy. A systematic review. Endocrinol. Metab. Clin. North Am.31(3), 779–793 (2002).
  • Kohner EM. Aspirin for diabetic retinopathy. Br. Med. J.327(7423), 1060–1061 (2003).
  • Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology113(9), 1533–1538 (2006).
  • Lam DS, Chan CK, Mohamed S et al. A prospective randomized trial of different doses of intravitreal triamcinolone for diabetic macular oedema. Br. J. Ophthalmol.91(2), 199–203 (2007).
  • Jonas JB. Intravitreal triamcinolone acetonide for diabetic retinopathy. Dev. Ophthalmol.39, 96–110 (2007).
  • Pearson P, Levy B; Fluconolone Acetonide Implant Study Group. Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 2-year results of a multi-center clinical trial. Program and abstracts of the Association for Research in Vision and Ophthalmology 2005 Annual Meeting, FL, USA (2005) (Abstract 4673).
  • Kuppermann BD, Blumenkranz MS, Haller JA et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch. Ophthalmol.125(3), 309–317 (2007).
  • Jaffe GJ. Update on pharmacologic treatment of diabetic macular edema. Retina Today2, 49–54 (2006).
  • Clermont A, Bursell SE, Feener EP. Role of the angiotensin II Type 1 receptor in the pathogenesis of diabetic retinopathy: effects of blood pressure control and beyond. J. Hypertens. Suppl.24(1), S73–S80 (2006).
  • Wilkinson-Berka JL. Angiotensin and diabetic retinopathy. Int. J. Biochem. Cell Biol.38(5–6), 752–765 (2006).
  • Sjolie AK, Porta M, Parving HH, Bilous R, Klein R. The DIRECT Programme Study Group. The Diabetic Retinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics. J. Renin Angiotensin Aldosterone Syst.6(1), 25–32 (2005).
  • Shams N, Ianchulev T. Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol. Clin. North Am.19(3), 335–344 (2006).
  • Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br. J. Ophthalmol.90, 1542–1547 (2006).
  • Caldwell RB, Bartoli M, Behzadian MA et al. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr. Drug Targets6(4), 511–5124 (2005).
  • Ng EW, Adamis AP. Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. Ann. NY Acad. Sci.1082, 151–171 (2006).
  • Cunningham ET Jr, Adamis AP, Altaweel MJ et al.; Macugen Diabetic Retinopathy Study Group. A Phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology112(10), 1747–1757 (2005).
  • Adamis AP, Altaweel M, Bressler NM et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology113(1), 23–28 (2006).
  • Yang JC, Haworth L, Sherry RM et al. Randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med.349(5), 427–434 (2003).
  • Avery RL, Pearlman J, Pieramici DJ et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology113(10), 1695–1705 (2006).
  • Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg. Lasers Imaging36(4), 331–335 (2005).
  • Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology113(3), 363–372 (2006).
  • Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology113(10), 1706–1712 (2006).
  • Sherris D. Ocular drug development – future directions. Angiogenesis10(2), 71–76 (2007).
  • Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous injection: a comprehensive review. Retina24(5), 676–698 (2004).
  • Kupperman BD. Transcleral uptake and diffusion of bevacizumab (Avastin) and ranibizumab (Lucentis). Retina Today2, 27–31 (2007).
  • Wilkinson-Berka JL, Wraight C, Werther G. The role of growth hormone, insulin-like growth factor and somatostatin in diabetic retinopathy. Curr. Med. Chem.13(27), 3307–3317 (2006).
  • Palii SS, Caballero S Jr, Shapiro G, Grant MB. Medical treatment of diabetic retinopathy with somatostatin analogues. Expert Opin. Investig. Drugs16(1), 73–82 (2007).
  • Boehm BO. Use of long-acting somatostatin analogue treatment in diabetic retinopathy. Dev. Ophthalmol.39, 111–121 (2007).
  • Gao BB, Clermont A, Rook S et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat. Med.13(2), 181–188 (2007).
  • Fletcher EL, Phipps JA, Wilkinson-Berka JL. Dysfunction of retinal neurons and glia during diabetes. Clin. Exp. Optom.88(3), 132–145 (2005).
  • Luttrull JK, Musch DC, Mainster MA. Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular oedema. Br. J. Ophthalmol.89(1), 74–80 (2005).

Website

  • International Diabetes Federation. Diabetes prevalence. www.idf.org/home/index.cfm?node=264

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.